• Solvay reported third quarter 2026 revenue of €1,136 million and net income of €66 million, and declared an interim dividend of €0.97 per share to be paid in January 2027.
• A long term offtake agreement for mixed rare earth carbonate between Viridis Mining and Minerals and Solvay's Rhodia Operations subsidiary adds contracted feedstock to support Solvay's rare earths business plans.
• The focus now turns to how Solvay's rare earth supply deal could influence the investment narrative around its ongoing transformation.

Seize this moment around Solvay's dividend and rare earths deal to compare it with a curated 33 best rare earth metal stocks that could be gearing up for their own supply driven rerating.

Solvay Investment Narrative Recap

To back Solvay, you need to believe the transformation towards higher value specialties like rare earths and more efficient production can offset pressure in soda ash and Coatis. The rare earth offtake deal and interim dividend sit against that backdrop. They reinforce that the group is still investing and returning cash, but they do not change the near term hinge on execution and cash discipline.

The biggest swing factor remains whether Solvay can convert its cost savings, digitalization and energy transition projects into cleaner earnings and stronger free cash flow. Key risks stay intact. Pricing pressure in core commodities, high debt and weak cash generation to date still frame the downside if margins and cash flow do not improve.

The long term rare earth supply agreement with Viridis connects directly to one of Solvay's clearest operational catalysts. The business already plans €15 to €20 million of investment to add heavy rare earth separation capacity in France by fall 2026. Secured Brazilian feedstock from 2028 through 2034 gives that plan more industrial backing and better visibility on volumes.

For you as a shareholder, the real question is execution. Expanding rare earth activities that are already about 8% of group sales could gradually shift Solvay's mix toward higher margin niches if projects run on time and on budget. Any delays, cost overruns or weaker demand for non Chinese rare earth capacity would blunt that effect and leave the group more exposed to commodity cycles and ongoing pricing pressure.

What The Current Solvay Forecasts Assume

Analysts sketch a Solvay profile where revenue edges down by 1.7% a year over the next three years while profit margins step up from 0.1% today to 5.6% by 2029. Earnings are projected to move from €4.0 million today to €242.9 million in 2029 on consensus, with the most optimistic forecasts reaching €523.3 million. That shift would sit on a modest 0.17% yearly increase in the share count.

On those numbers, the stock would be trading on a P/E of 13.6x in 2029 compared with 646.6x today. This uses an 8.31% discount rate in the Simply Wall St framework and a sector context where GB Chemicals trades on 15.6x. Taken together, that setup implies a rerating that arises less from a high multiple and more from profit expanding into mid single digit margins while reported revenue drifts lower.

Solvay's narrative projects €4.3 billion revenue and €242.9 million earnings by 2029. This assumes a 1.7% yearly revenue decline and an earnings increase of about €238.9 million from €4.0 million today.

Uncover why Solvay's fair value indicates a valuation gap that appears to be roughly in line with its current price.

Exploring Other Perspectives

One bearish twist you might want to explore is energy costs. The lowest analysts were working off revenue drifting toward about €4.2b and earnings near €212.8 million by 2029, assuming high European power and carbon prices kept margins tight. That view did not yet factor in Solvay’s latest dividend decision or the rare earth offtake deal, so it could shift. Use this as a prompt to compare several narratives rather than rely on a single story.

Explore 2 other Solvay fair value estimates, including one that suggests it could be worth just €24.77.

Reach Your Own Conclusion

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

• A great starting point for your Solvay research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• See our latest analysis for Solvay. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Solvay's overall financial health at a glance.

Looking For More Investment Ideas Beyond Solvay?

If Solvay has helped sharpen your thinking on cash flow quality, balance sheet strength and income potential, use that same framework to scan a wider watchlist with the Simply Wall St Screener.

• If you want potential upside with more financial resilience, start with a 224 high quality undervalued stocks that already combine solid balance sheets with healthy cash generation.
• For steadier income streams, focus on payouts by reviewing a 232 dividend fortresses that currently offer yields from established businesses.
• When capital preservation matters most, narrow your search to a 212 resilient stocks with low risk scores that score well on financial health and volatility.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.